The University at Buffalo in collaboration with Tetra Therapeutics took a major step in the discovery of a new drug offering first-class treatment for Fragile X Syndrome – a leading genetic cause of autism. The drug, BPN14770, was used on adult male patients with Fragile X Syndrome and showed positive results in phase 2 clinical […]